135367-08-7

Upstream product

• 134052-62-3 3β-(4-aminophenyl)tropane-2β-carboxylic acid methyl ester 
• 50373-10-9 methyl ecgonidine 
• 174224-35-2 2β-carbomethoxy-3β-(4'-trimethylsilylphenyl)tropane 
• 18620-02-5 (4-bromophenyl)magnesium bromide 
• 127279-73-6 3β-(4-nitrophenyl)tropane-2β-carboxylic acid methyl ester 
• 50370-54-2 3β-phenyltropane-2β-carboxylic acid methyl ester 
• 50373-10-9 (R)-(-)-anhydroecgonine methyl ester 
• 17878-43-2 [4-(trimethylsilyl)phenyl]magnesium bromide 

Downstream Products

• 181796-42-9 3β-(4'-vinylphenyl)tropane-2β-carboxylic acid methyl ester 
• 303733-94-0 N-(2,2,2-trichloroethylcarbamoyl)-2β-carbomethoxy-3β-(4-bromophenyl)nortropane 
• 150583-19-0 3β-[4-Bromophenyl]tropan-2β-Carboxylic Acid 
• 869845-24-9 2β-carbomethoxy-3β-(4'-(3-furyl)phenyl)tropane 
• 303731-40-0 (1R,2S,3S,5S)-3-[4-(3-Hydroxy-propyl)-phenyl]-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester 
• 303731-39-7 (1R,2S,3S,5S)-3-[4-(2-Hydroxy-ethyl)-phenyl]-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid methyl ester 
• 805255-44-1 MCL-323 
• 805255-21-4 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid 3-methanesulfonyloxy-propyl ester 
• 805255-23-6 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid 3-fluoro-propyl ester 
• 805255-27-0 MCL 322 
• 805255-40-7 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid 2-hydroxy-ethyl ester 
• 805255-30-5 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-aza-bicyclo[3.2.1]octane-2-carboxylic acid 2-fluoro-ethyl ester 
• 185348-32-7 (1R,2S,3S,5S)-3-(4-Bromo-phenyl)-8-methyl-8-aza-bicyclo[3.2.1]octane-2-carbonyl chloride 
• 869845-40-9 3β-(4'-(3-furyl)phenyl)tropane-2β-carboxylic acid 

Relevant academic research and scientific papers

Fluoralkenyl nortropanes

Provided are compounds of the following formula: wherein R is C2-C6 mono- or multi-unsaturated hydrocarbon having one or more ethylene, acetylene or allene groups, A is 18 or 19, and X is H or halogen. The compounds of the invention bind to dopamine transporter with high affinity and selectivity and are thus useful as diagnostic and therapeutic agents for diseases associated with dopamine transporter dysfunction. The radiolabeled compounds are useful as imaging agents for visualizing the location and density of dopamine transporter by PET imaging.

Synthesis and biological evaluation of a series of novel N- or O-fluoroalkyl derivatives of tropane: Potential positron emission tomography (PET) imaging agents for the dopamine transporter

A series of novel fluoroalkyl-containing tropane derivatives was synthesized, and their binding affinities for the dopamine transporter (DAT), serotonin transporter (SERT), and norepinephrine transporter (NET) were determined via competitive binding assays. Among these derivatives, the fluoropropyl ester of β-CIT (19), the fluoroethyl ester of β-CIT (20), the N-fluoropropyl derivative of β-CBT (12), and the fluoropropyl ester of β-CMT (18) displayed higher affinity and greater selectivity for the DAT versus SERT and NET than FP-CIT, which indicates that they are attractive candidates for the development of 18F-labeled PET imaging agents for the DAT.

Synthesis, ligand binding, QSAR, and CoMFA study of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters

A series of 3β-(p-substituted phenyl)tropane-2β-carboxylic acid methyl esters (2) were synthesized and found to possess high affinity for the cocaine binding site in rat striatum. The p-chloro (2c) and p-iodo (2n) compounds, which were the most potent analogues prepared, were found to be 85 and 78 times more potent than (-)-cocaine. The p-bromo (2m) and p-methyl (2d) were also 56 and 60 times more potent than cocaine. QSAR and CoMFA studies were conducted to correlate binding affinity of the cocaine analogues with their structural features. Whereas the QSAR study gave relatively low correlations, the CoMFA study gave a correlation with high predictive value.